Immune to Cancer: The CRI Blog
-
Checkpoint Immunotherapy Combination Approved for First-line Treatment of Advanced Kidney Cancer
The combination of checkpoint immunotherapies against PD-1 and CTLA-4 significantly improved survival and response rates compared to…
-
AACR18 Day 2 Update: What’s Next for Cancer Immunotherapy?
CRI scientists kicked off the opening plenary session at AACR18 and discussed several promising avenues of immunotherapy…
-
AACR18: Driving Innovative Cancer Science to Patient Care
This year’s annual AACR meeting boasts an impressive lineup of presentations highlighting both clinical and preclinical immunotherapy…
-
Healthcare Experts Tackle Tough Challenges at Fortune Brainstorm HEALTH 2018
CRI CEO highlights next steps in immunotherapy’s advancement at Fortune’s premier healthcare conference
-
How Man’s Best Friend Could Help Us Cure Cancer
Cancer very is similar in dogs and humans, and scientists are now exploring how cures for one…
-
CICON17 Day 4 Recap: The Tumor Microenvironment and Oncolytic Viruses
The final day of CICON17 explored two newer immunotherapy approaches that reflect broader understanding of tumor-immune interactions…
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
-
CICON17 Day 1 Recap: Neoantigens, Vaccines, and Overcoming Immunotherapy Resistance
Day 1 of CICON17 explored how to identify and target neoantigens with vaccines and other strategies to…
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential